New GSK: strategy and growth outlook

Investor update

Speaker biographies

23 June 2021
Emma Walmsley has been GSK CEO and Board Director since April 2017.

Prior to this Emma was the CEO of GSK Consumer Healthcare, a Joint Venture between GSK and Novartis, from its creation in March 2015, and has been a member of GSK’s Corporate Executive Team since 2011. She joined GSK in 2010, with responsibility for Consumer Healthcare, Europe.

Prior to joining GSK, Emma worked with L’Oreal for 17 years where she held a variety of global and local marketing and general management roles in Paris, London and New York. From 2007 she was based in Shanghai as General Manager, Consumer Products for L’Oreal China.

Emma joined the Microsoft board as an independent director in December 2019. She was a Non-Executive Director of Diageo plc from January to September 2016.

Emma was appointed Dame (DBE) for services to the pharmaceutical industry and business in the 2020 British Honours.

Emma holds an MA in Classics and Modern Languages from Oxford University.

Iain Mackay has joined GSK and was appointed to the Board as Chief Financial Officer Designate on 14 January 2019. He became Chief Financial Officer on 1 April 2019. He is a member of the Corporate Executive Team.

Iain is responsible for Global Finance and several of the company’s key global functions including Investor Relations and Tech.

Skills and experience

Prior to joining GSK, Iain was Group Finance Director at HSBC Holdings plc, a position he held for eight years. A chartered accountant, Iain has worked in Asia, the US and Europe and before HSBC was at General Electric, Schlumberger Dowell and Price Waterhouse. Iain was previously a Trustee of the British Heart Foundation and Chair of its Audit and Risk Committee.

Iain holds an MA in Business Studies and Accounting and holds an Honorary Doctorate from Aberdeen University in Scotland.

Iain is a member of the Institute of Chartered Accountants of Scotland.

External appointments

- Member, Court of the University of Aberdeen and Chair of its Remuneration Committee
- Member, The 100 Group and Chair of its Stakeholder Communications and Reporting Committee

Iain is a member of the Corporate Executive Team.

Skills and experience

Prior to joining GSK, Iain was Group Finance Director at HSBC Holdings plc, a position he held for eight years. A chartered accountant, Iain has worked in Asia, the US and Europe and before HSBC was at General Electric, Schlumberger Dowell and Price Waterhouse. Iain was previously a Trustee of the British Heart Foundation and Chair of its Audit and Risk Committee.

Iain holds an MA in Business Studies and Accounting and holds an Honorary Doctorate from Aberdeen University in Scotland.

Iain is a member of the Institute of Chartered Accountants of Scotland.

External appointments

- Member, Court of the University of Aberdeen and Chair of its Remuneration Committee
- Member, The 100 Group and Chair of its Stakeholder Communications and Reporting Committee
**Speaker biographies**

**Dr. Hal Barron**  
**Chief Scientific Officer and President, R&D**

Hal joined GSK as Chief Scientific Officer and President, R&D on 1 January 2018. He was also appointed to the GSK Board of Directors as an Executive Director.

Hal is responsible for all research and development of our pipeline molecules as well as life-cycle management of the approved medicines. He is a member of the Corporate Executive Team.

**Skills and experience**

Prior to joining GSK, Hal was President, R&D at Calico LLC (California Life Company), an Alphabet-funded company that uses advanced technologies to increase understanding of lifespan biology. Prior to this, Hal was Executive Vice President, Head of Global Product Development, and Chief Medical Officer of Roche, responsible for all the products in the combined portfolio of Roche and Genentech. At Genentech, he was Senior Vice President of Development and Chief Medical Officer. Hal was a Non-Executive Director and Chair of the Science & Technology Committee at Juno Therapeutics, Inc until March 2018, when it was acquired by Celgene Corporation.

He holds a Bachelor of Science degree in Physics from Washington University in St Louis and a medical degree from Yale University. He completed his training in Cardiology and Internal Medicine at the University of California, San Francisco.

Hal has been issued several patents for his work in thrombosis and angiogenesis and has published more than 90 papers in peer-reviewed scientific journals.

**External appointments**

- Associate Adjunct Professor, Epidemiology & Biostatistics, University of California, San Francisco
- Non-Executive Board Director, GRAIL, Inc, an early cancer detection healthcare company
- Advisory Board Member, Verily Life Sciences LLC, a subsidiary of Alphabet, Inc

He holds a Bachelor of Science degree in Biology from Flinders University in Adelaide and an MBA from the Macquarie University, Sydney.

**Luke Miels**  
**Chief Commercial Officer**

Luke joined GSK in September 2017. He is a member of the Corporate Executive Team.

At GSK, he is responsible for commercialising a portfolio of medicines and vaccines with annual sales of more than £20 billion and operations in over 100 markets.

His previous role was Executive Vice President of AstraZeneca’s European business and, prior to that, Executive Vice President of Global Product and Portfolio Strategy, Global Medical Affairs and Corporate Affairs.

Luke joined AstraZeneca from Roche, where he was Regional Vice President Asia Pacific for the Pharmaceuticals Division. Before then, he held roles of increasing seniority at Sanofi-Aventis in Asia and the US. He also co-led the US integration of Sanofi and Aventis. Prior to that, he held general management roles in Thailand and New Zealand, following his entry into the industry in Australia.

He holds a Bachelor of Science degree in Biology from Flinders University in Adelaide and an MBA from the Macquarie University, Sydney.
Roger Connor  
**President, Global Vaccines**

Roger was appointed President of GSK Global Vaccines in 2018. In addition to leadership of the Vaccines business, he is responsible for GSK’s global procurement organisation. He has been a Member of the Corporate Executive Team since 2013.

**Skills and experience**

Roger has deep and broad experience in the pharmaceutical industry. He has held a number of roles in finance, corporate strategy and manufacturing, most recently running GSK’s global pharmaceutical and consumer healthcare manufacturing organisation from 2013 to 2018. In this role he managed 75 sites across more than 30 countries, and was accountable for the leadership of 33,000 employees. Roger holds a degree in Mechanical and Manufacturing Engineering from Queen’s University, Belfast and a Master’s in Manufacturing Leadership from Cambridge University. He is a Chartered Accountant.

**External appointments**

- Member of the Board of Gavi, the Vaccine Alliance
- Chair of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) CEO Vaccines Committee

Deborah Waterhouse  
**Chief Executive Officer of ViiV Healthcare**

Deborah Waterhouse was appointed to GSK’s Corporate Executive Team on 8 January 2020. She became Chief Executive Officer of ViiV Healthcare on 1 April 2018. ViiV Healthcare is majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders.

Deborah joined GSK in 1996 and was most recently the Senior Vice President of Primary Care within the company’s US business, prior to which she led the US Vaccines business.

She brings a wealth of experience to GSK having lived and worked in Europe, Asia Pacific and the USA, and a strong track record of performance in both specialty and primary care. Deborah led the HIV business in the UK before heading the HIV Centre of Excellence for Pharma Europe, and held international roles as General Manager of Australia and New Zealand and Senior Vice President for Central and Eastern Europe.
Dr. Kimberly Smith
Head of R&D, ViiV Healthcare

As the head of research and development for ViiV Healthcare, Dr. Kimberly Smith MD, MPH oversees the clinical development of our pipeline assets in support of our overall company strategy to deliver meaningful advances in treatment and care for people living with HIV.

Dr. Smith is a graduate of the University of Michigan School of Medicine and also holds a MPH degree from the University of Michigan School of Public Health. She completed her internship, residency, and Infectious Disease fellowship at Rush University Medical Centre in Chicago. Following her training she joined the faculty of the Section of Infectious Disease at Rush University Medical Center in Chicago.

Prior to joining ViiV Healthcare in late 2013, Dr. Smith served as the Principle Investigator of the Rush University Medical Center Clinical Research Site of the AIDS Clinical Trials Group (ACTG). Dr. Smith also served as the chair of the ACTG Underrepresented Populations committee and chair of multiple ACTG clinical trials.

She has been a member of NIH study sections, the HIVMA Board of Directors, the CDC Board of Scientific Counselors and numerous advisory committees. Dr. Smith has published over 150 articles, abstracts and manuscripts and she co-edited one of the few books, HIV/AIDS in U.S. Communities of Color, which addressed the HIV epidemic among minorities in the US.

In addition to her research activities, Dr. Smith has been an active HIV clinician, clinical educator, community leader and advocate. She has lectured at countless local national and international conferences including the Conference on Retroviruses and Opportunistic Infections (CROI), the International AIDS Conference, The International Conference on Antimicrobial Agents and Chemotherapy, and Infectious Disease Society of America.
Contact: GSK Investor Relations Team

+44 (0)20 8047 5000 or at GSK.Investor-Relations@gsk.com

New GSK, uniting science, talent and technology to get ahead of disease together